Drug Database
Back to search

Poland· PL-100462033

Obsidan

A ferrous glycine sulfate product containing ferrosi sulfas heptahydricus, registered in Poland by Teofarma s.r.l.. The same ATC class is registered in 5 of our 19 countries.

ATC B03AA01

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedObsidanATCB03AA01REGISTER NO.PL-100462033PACKS LISTED6CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about ferrosi sulfas heptahydricusAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Ferrous glycine sulfate is registered in 5 of 19 countries.

Countries holding a registration under ATC B03AA01 (ferrous glycine sulfate), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 4 of them publish a price we can compare per daily dose
Search ferrous glycine sulfate products by name

Ferrous glycine sulfate · ATC B03AA01

5 / 19 countries

  • Denmark
  • Finlandprice
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of ferrous glycine sulfate costs, country by country.

Normalised to the WHO defined daily dose (0.2 g), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Ferrous glycine sulfate · price per daily dose (0.2 g)

USD · FX 28 Sept 2026

  • CH Switzerland$0.61
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Ferrosi sulfas heptahydricus
Manufacturer
Teofarma s.r.l.
Country
Poland (PL)
ATC code
B03AA01
ATC class
Ferrous glycine sulfate
Defined daily dose
0.2 g, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 6

  • gtin
    05909991507534
  • gtin
    05909991507541
  • gtin
    05909991507558
  • gtin
    05413787220052
  • gtin
    05413787220069
  • gtin
    08033622633402

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

10 interactions on record for ferrous glycine sulfate.

Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check ferrous glycine sulfate against other medicinesHow interaction checks work

Ferrous glycine sulfate · interactions on record

10 records

10 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
Mechanism and what to do, in the interaction check
Interaction register. Grades as the source publishes them.

Same medicine, other countries

Ferrous glycine sulfate in 12 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All ferrous glycine sulfate products

Authorised across Europe · EMA

The same active substance is authorised in 13 EEA countries. Names it is sold under:

  • Austria · Ferro - Gradumet
  • Belgium · Fero-Gradumet
  • Germany · Eisensulfat Lomapharm, Ferro Aiwa
  • Spain · Ferogradumet
  • France · Fer Nouveau-Ne Ap-Hp
  • United Kingdom (Northern Ireland) · Feospan, Ferrous Sulfate Wockhardt Uk
  • Greece · Tardyferon
  • Hungary · Ferro-Gradumet
  • Lithuania · Tardyferon
  • Luxembourg · Fero-Gradumet
  • Norway · Duroferon, Ferromax
  • Portugal · Ferro-Gradumet
  • Slovakia · Tardyferon

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/616e3611-2c17-4483-8741-da43cadeb676
GET /v1/drugs/616e3611-2c17-4483-8741-da43cadeb676?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Kapsułki dojelitowe, twarde",
  "source": "urpl",
  "strength": "567,66 mg",
  "packaging": "05909991507534 ¦ Rp ¦ 148827\n500 kaps.\n05909991507541 ¦ Rp ¦ 148828\n90 kaps.\n05909991507558 ¦ Rp ¦ 148829\n30 kaps.\n05413787220052 ¦ Rp ¦ Skasowane ¦ 148830\n50 kaps.\n05413787220069 ¦ Rp ¦ 150731\n100 kaps.\n08033622633402 ¦ Rp ¦ 168030\n50 kaps.",
  "substance": "Kompleks żelaza siarczan (II) pięciowodny z glicyną 567.66 mg",
  "common_name": "Ferrosi sulfas heptahydricus",
  "pl_product_id": "100462033",
  "pozwolenie_nr": "27644",
  "auth_procedure": "MRP",
  "authorisation_validity": "2028-02-06"
}
API referenceMCP serverPlans

See everything about ferrous glycine sulfate.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console